AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Quest Diagnostics Incorporated (NYSE:DGX)
171.38 USD
-0.370 0.215%Sponsored Reports
Loading...
| Previous Close (in USD) | 171.75 |
|---|---|
| Change | -0.370 0.215% |
| 52 W H/L (in USD) | 155.143/118.897 |
| EBITDA (in USD) | 1705M |
| PE Ratio | 20.38 |
| Volume | 465431 |
| Diluted Eps TTM | 6.71 |
| Total Assets (in USD) | 12837M |
|---|---|
| Total Liabilities (in USD) | 6830M |
| Revenue TTM (in USD) | 9297M |
| Cash (in USD) | 315M |
| Market Cap (in USD) | 15,374.363 M |
| Revenue Per Share TTM | 82.824 |
| Gross Profit TTM (in USD) | 3467M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
Quest Diagnostics Incorporated
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Employees: 50000
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Stephen H. Rusckowski | Exec. Chairman | 1957 |
| 2. | Mr. James E. Davis | CEO, Pres & Director | 1963 |
| 3. | Ms. Catherine T. Doherty | Sr. VP of Regional Bus.es | 1963 |
| 4. | Mr. Sam A. Samad | Exec. VP & CFO | 1970 |
| 5. | Mr. Michael J. Deppe | VP, Corp. Controller & Chief Accounting Officer | 1967 |
| 6. | Ms. Gabrielle Wolfson | Sr. VP and Chief Information & Digital Officer | NA |
| 7. | Mr. Shawn C. Bevec | VP of Investor Relations | NA |
| 8. | Mr. Michael E. Prevoznik | Sr. VP & Gen. Counsel | 1962 |
| 9. | Ms. Kristin Lee Wallace Esq. | Sr. VP of Compliance | NA |
| 10. | Mr. Gary D. Samuels | Sr. VP & Chief Communications Officer | NA |
Peers
Sector: Healthcare
Industry: Diagnostics & Research
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
TMO
Thermo Fisher Scientific Inc |
+7.369 1.388% | 533.78 | 34.710 | 23.866 | 4.622 | 4.428 | 5.293 | 20.886 |
|
DHR
Danaher Corporation |
+3.140 1.532% | 206.57 | 29.090 | 28.011 | 5.669 | 3.198 | 5.999 | 19.094 |
|
A
Agilent Technologies Inc |
-0.090 0.066% | 137.66 | 34.360 | 26.385 | 6.587 | 7.136 | 6.781 | 23.557 |
|
IDXX
IDEXX Laboratories Inc |
+3.010 0.667% | 451.62 | 49.990 | 45.662 | 11.293 | 27.850 | 11.461 | 34.457 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | 1235M | 2599M | 1884M | 1076M | 926M |
| Minority Interest | -69M | -85M | 68M | 48M | 52M |
| Net Income | 946M | 1995M | 1431M | 858M | 736M |
| Selling General Administrative | 1818M | 1727M | 1550M | 1457M | 1424M |
| Gross Profit | 3433M | 4209M | 3633M | 2689M | 2605M |
| Reconciled Depreciation | 437M | 408M | 361M | 329M | 309M |
| Ebit | 1428M | 2381M | 1971M | 1231M | 1097M |
| Ebitda | 1810M | 3158M | 2408M | 1580M | 1406M |
| Depreciation And Amortization | 382M | 777M | 437M | 349M | 309M |
| Operating Income | 1428M | 2381M | 1971M | 1231M | 1101M |
| Other Operating Expenses | 8455M | 8407M | 7466M | 6495M | 6426M |
| Interest Expense | 138M | 151M | 163M | 175M | 167M |
| Tax Provision | 264M | 597M | 460M | 247M | 182M |
| Interest Income | 138M | 151M | 163M | 5M | 2M |
| Net Interest Income | -138M | -151M | -163M | -175M | -167M |
| Income Tax Expense | 264M | 597M | 460M | 247M | 182M |
| Total Revenue | 9883M | 10788M | 9437M | 7726M | 7531M |
| Total Operating Expenses | 2005M | 1828M | 1662M | 1458M | 1500M |
| Cost Of Revenue | 6450M | 6579M | 5804M | 5037M | 4926M |
| Total Other Income Expense Net | -193M | 218M | -87M | -155M | -12M |
| Net Income From Continuing Ops | 1015M | 2080M | 1499M | 886M | 744M |
| Net Income Applicable To Common Shares | 942M | 1988M | 1431M | 858M | 736M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Total Assets | 12837M | 13611M | 14026M | 12843M | 11003M |
| Intangible Assets | 1092M | 1167M | 1167M | 1121M | 1207M |
| Other Current Assets | 196M | 223M | 157M | 112M | 144M |
| Total Liab | 6830M | 7049M | 7135M | 7080M | 5659M |
| Total Stockholder Equity | 5893M | 6444M | 6759M | 5641M | 5216M |
| Other Current Liab | 1072M | 1243M | 1187M | 778M | 782M |
| Common Stock | 2M | 2M | 2M | 2M | 2M |
| Capital Stock | 2M | 2M | 2M | 2M | 2M |
| Retained Earnings | 8290M | 7649M | 9303M | 8174M | 7602M |
| Good Will | 7220M | 7095M | 6873M | 6619M | 6563M |
| Other Assets | 144M | 163M | 1301M | 64M | 56M |
| Cash | 315M | 872M | 1158M | 1192M | 135M |
| Cash And Equivalents | 315M | 872M | 1158M | 1192M | 135M |
| Total Current Liabilities | 1551M | 1753M | 1776M | 1990M | 1485M |
| Current Deferred Revenue | - | - | - | - | 17M |
| Net Debt | 4307M | 3785M | 3497M | 4136M | 3758M |
| Short Term Debt | 155M | 153M | 143M | 949M | 464M |
| Short Long Term Debt | 2M | 2M | 2M | 892M | 562M |
| Short Long Term Debt Total | 4622M | 4657M | 4655M | 5328M | 3893M |
| Other Stockholder Equity | -2378M | -1193M | -2525M | -2496M | -2329M |
| Property Plant Equipment | 2351M | 2304M | 1627M | 1453M | 1288M |
| Total Current Assets | 1898M | 2741M | 3058M | 2490M | 1390M |
| Long Term Investments | 132M | 141M | 521M | 482M | 436M |
| Short Term Investments | - | - | 521M | - | - |
| Net Receivables | 1195M | 1438M | 1520M | 1063M | 1012M |
| Long Term Debt | 3978M | 4010M | 4013M | 3966M | 3429M |
| Inventory | 192M | 208M | 223M | 123M | 99M |
| Accounts Payable | 324M | 357M | 446M | 263M | 222M |
| Accumulated Other Comprehensive Income | -21M | -14M | -21M | -39M | -59M |
| Non Currrent Assets Other | 144M | 163M | 176M | 160M | 119M |
| Non Current Assets Total | 10939M | 10870M | 10968M | 10353M | 9613M |
| Capital Lease Obligations | 642M | 645M | 640M | 558M | - |
| Long Term Debt Total | 3978M | 4010M | 4013M | 3966M | 3429M |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -543M | 752M | -772M | -411M | -801M |
| Total Cashflows From Investing Activities | -543M | 21M | -772M | -411M | -801M |
| Total Cash From Financing Activities | -1732M | -2540M | -1267M | 225M | -401M |
| Net Income | 1015M | 2080M | 1499M | 906M | 788M |
| Change In Cash | -557M | -286M | -34M | 1057M | -2M |
| Begin Period Cash Flow | 872M | 1158M | 1192M | 135M | 137M |
| End Period Cash Flow | 315M | 872M | 1158M | 1192M | 135M |
| Total Cash From Operating Activities | 1718M | 2233M | 2005M | 1243M | 1200M |
| Depreciation | 437M | 408M | 361M | 329M | 309M |
| Other Cashflows From Investing Activities | -139M | 424M | -354M | -11M | -418M |
| Dividends Paid | -305M | -309M | -297M | -286M | 266M |
| Change To Inventory | - | -20M | - | 29M | 4M |
| Sale Purchase Of Stock | -1408M | -2199M | -325M | -353M | -322M |
| Other Cashflows From Financing Activities | -17M | -159M | -29M | -87M | -36M |
| Capital Expenditures | 404M | 403M | 418M | 400M | 383M |
| Change In Working Capital | 119M | 87M | 22M | 35M | -49M |
| Other Non Cash Items | 69M | -364M | -59M | -98M | 18M |
| Free Cash Flow | 1314M | 1830M | 1587M | 843M | 817M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 1 year ago | 3520338 |
| 2. | Vanguard Institutional 500 Index Trust | 1 year ago | 2734705 |
| 3. | Vanguard Mid Cap Index Institutional | 1 year ago | 2552218 |
| 4. | Victory Sycamore Established Value R | 1 year ago | 2266000 |
| 5. | Vanguard Windsor Investor Shares | 1 year ago | 1765925 |
| 6. | Fidelity® 500 Index | 1 year ago | 1299530 |
| 7. | SPDR® S&P 500 ETF Trust | 1 year ago | 1263399 |
| 8. | American Century Mid Cap Value Inv | 1 year ago | 1228797 |
| 9. | American Century U.S. Mid Cap Value | 1 year ago | 1228797 |
| 10. | iShares Core S&P 500 ETF | 1 year ago | 1106400 |
| 11. | Vanguard Value Index Inv | 1 year ago | 961587 |
| 12. | Vanguard Mid-Cap Value ETF | 1 year ago | 903411 |
| 13. | T. Rowe Price US Large-Cap Core | 1 year ago | 893690 |
| 14. | T. Rowe Price US Large-Cap Core Eq Comp | 1 year ago | 893690 |
| 15. | Health Care Select Sector SPDR® ETF | 1 year ago | 867622 |
| 16. | JPM US Mid Cap Value-Composite | 1 year ago | 842687 |
| 17. | JPMorgan Mid Cap Value L | 1 year ago | 842687 |
| 18. | JPM US Mid Cap Value-MA | 1 year ago | 842687 |
| 19. | GMO Quality IV | 1 year ago | 835119 |
| 20. | GMO Quality Composite | 1 year ago | 835119 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Group Inc | 1 year ago | 13624131 |
| 2. | BlackRock Inc | 1 year ago | 11386506 |
| 3. | State Street Corporation | 1 year ago | 5341405 |
| 4. | American Century Companies Inc | 1 year ago | 3554517 |
| 5. | Victory Capital Management Inc. | 1 year ago | 3414514 |
| 6. | Wellington Management Company LLP | 1 year ago | 2613793 |
| 7. | Geode Capital Management, LLC | 1 year ago | 2473564 |
| 8. | T. Rowe Price Associates, Inc. | 1 year ago | 2207711 |
| 9. | JPMorgan Chase & Co | 1 year ago | 2001347 |
| 10. | Dimensional Fund Advisors, Inc. | 1 year ago | 1972866 |
| 11. | Amvescap Plc. | 1 year ago | 1798803 |
| 12. | Davis Selected Advisers | 1 year ago | 1667698 |
| 13. | Grantham, Mayo, Van Otterloo & Co., LLC | 1 year ago | 1636407 |
| 14. | Morgan Stanley - Brokerage Accounts | 1 year ago | 1633585 |
| 15. | Wells Fargo & Co | 1 year ago | 1574848 |
| 16. | Northern Trust Corp | 1 year ago | 1319885 |
| 17. | FMR Inc | 1 year ago | 1305532 |
| 18. | UBS Asset Mgmt Americas Inc | 1 year ago | 1268575 |
| 19. | Bank of America Corp | 1 year ago | 1110864 |
| 20. | Nordea Investment Mgmt Bank Demark A/s | 1 year ago | 999019 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Related Articles
Loading...
